Nils Bergenhem

Biography

Dr. Bergenhem joined AdipoGenix in June 2005 as Chief Scientific Officer. He has over 16 years of experience in the metabolic disease arena, which includes managing drug discovery and development. Prior to joining AdipoGenix he was Vice President of Research at the Institute for Diabetes Discovery (IDD), where he managed the development of small molecule drugs for the treatment of diabetes, diabetic complications, and obesity. Before joining IDD, Dr. Bergenhem held the position as Director for Diabetes Research at OSI Pharmaceuticals Inc. and was responsible for building OSI’s diabetes program in New York as well as Oxford, England. Prior to OSI Pharmaceuticals, Dr. Bergenhem, was employed by Novo Nordisk in Copenhagen, heading up a department focused on addressing dyslipideamia in type 2 diabetics. Dr. Bergenhem has extensive experience managing international collaborative programs, in the Novo Nordisk - Boehringer Ingelheim collaboration, as well as scientific manager of the OSI - Tanabe Seiyaku CO., Ltd. programs. Dr. Bergenhem holds a BS degree in Chemistry from Linkoping University, Sweden, and a Ph.D. in Biochemistry from Umeaa University, Sweden. He has completed postdoctoral work at University of Michigan in Molecular Biology and Human Genetics, where he also spent three years at the School of Medicine as Research Investigator at the Institute of Gerontology and at the Department of Biological Chemistry. 

Research Interest

 Development of small molecule drugs for the treatment of diabetes, diabetic complications, and obesity